MH
Publicaties op Oncologisch.com
INDUCE-3: A Gerandomiseerde Fase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent...
A Pooled Analysis of Datopotamab Deruxtecan in Patiënten met EGFR-Mutated NSCLC.
Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA).
Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Gevorderd or Metastatic Non-Small Cell Lung Cancer: Th...
Preoperatieve durvalumab of durvalumab plus tremelimumab bij hoofd-halscarcinoom: fase II
Tiragolumab plus atezolizumab plus chemo bij uitgebreid SCLC: SKYSCRAPER-02 fase III